Imago BioSciences
Wan-Jen Hong joined Imago in May 2021 as the Chief Medical Officer. Prior to joining Imago, Dr. Hong was a Group Medical Director at Genentech, where she spent 7 years in the late-stage clinical development group. She worked on the development of several molecules across multiple indications in hematology/oncology and played a leading role in the indication expansion for venetoclax in AML.
Dr. Hong received a B.S in chemical engineering and biology from Massachusetts Institute of Technology and a M.D. from Stanford University. She completed her clinical training in internal medicine and hematology/oncology at Stanford University and is an adjunct clinical faculty member in the Division of Hematology at Stanford.
This person is not in any offices
Imago BioSciences
Our scientific initial efforts are aimed at developing drugs that improve the management of proliferative diseases of the bone marrow using an LSD1 inhibitor